Galera Therapeutics Inc
OTC:GRTX
Cash Flow Statement
Cash Flow Statement
Galera Therapeutics Inc
| Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||||||||||||||
| Net Income |
(34)
|
(36)
|
(44)
|
(52)
|
(60)
|
(67)
|
(71)
|
(74)
|
(75)
|
(78)
|
(84)
|
(81)
|
(77)
|
(69)
|
(63)
|
(62)
|
(64)
|
(71)
|
(70)
|
(59)
|
(46)
|
(29)
|
(20)
|
(19)
|
(16)
|
(13)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Change in Deffered Taxes |
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
|
| Stock-Based Compensation |
1
|
2
|
2
|
2
|
3
|
4
|
5
|
6
|
6
|
6
|
7
|
7
|
7
|
8
|
7
|
7
|
7
|
5
|
5
|
6
|
4
|
4
|
3
|
3
|
2
|
1
|
|
| Other Non-Cash Items |
2
|
3
|
4
|
6
|
7
|
8
|
10
|
10
|
11
|
11
|
13
|
14
|
16
|
17
|
18
|
15
|
17
|
22
|
20
|
20
|
15
|
7
|
6
|
8
|
7
|
7
|
|
| Change in Working Capital |
1
|
2
|
1
|
(1)
|
3
|
3
|
3
|
4
|
1
|
3
|
4
|
(3)
|
(3)
|
(4)
|
(3)
|
3
|
4
|
3
|
1
|
(6)
|
(8)
|
(8)
|
(6)
|
(1)
|
(0)
|
(2)
|
|
| Cash from Operating Activities |
(31)
N/A
|
(30)
+3%
|
(38)
-26%
|
(47)
-23%
|
(50)
-7%
|
(56)
-12%
|
(58)
-4%
|
(60)
-2%
|
(62)
-5%
|
(64)
-2%
|
(67)
-5%
|
(68)
-1%
|
(64)
+6%
|
(56)
+12%
|
(47)
+16%
|
(43)
+7%
|
(44)
-1%
|
(46)
-4%
|
(49)
-7%
|
(45)
+8%
|
(38)
+15%
|
(30)
+21%
|
(20)
+34%
|
(12)
+38%
|
(10)
+21%
|
(8)
+13%
|
|
| Investing Cash Flow | |||||||||||||||||||||||||||
| Capital Expenditures |
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(1)
|
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
|
| Other Items |
(56)
|
(65)
|
(37)
|
(27)
|
(34)
|
(23)
|
(22)
|
37
|
54
|
60
|
3
|
6
|
2
|
(7)
|
41
|
24
|
19
|
20
|
26
|
27
|
22
|
14
|
4
|
(0)
|
0
|
0
|
|
| Cash from Investing Activities |
(56)
N/A
|
(66)
-17%
|
(38)
+43%
|
(28)
+26%
|
(35)
-25%
|
(24)
+32%
|
(22)
+7%
|
37
N/A
|
54
+47%
|
60
+11%
|
2
-96%
|
5
+114%
|
2
-55%
|
(7)
N/A
|
41
N/A
|
24
-41%
|
19
-20%
|
20
+5%
|
26
+29%
|
27
+5%
|
22
-19%
|
14
-34%
|
4
-72%
|
(0)
N/A
|
0
N/A
|
0
N/A
|
|
| Financing Cash Flow | |||||||||||||||||||||||||||
| Net Issuance of Common Stock |
70
|
0
|
0
|
58
|
58
|
58
|
58
|
1
|
1
|
7
|
9
|
9
|
10
|
4
|
1
|
4
|
30
|
30
|
32
|
29
|
2
|
2
|
(0)
|
2
|
3
|
3
|
|
| Net Issuance of Debt |
20
|
40
|
40
|
20
|
40
|
20
|
20
|
20
|
0
|
20
|
58
|
58
|
0
|
38
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other |
0
|
69
|
68
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
2
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Cash from Financing Activities |
90
N/A
|
109
+21%
|
38
-65%
|
78
+104%
|
98
+26%
|
79
-19%
|
80
+1%
|
21
-74%
|
1
-96%
|
27
+3 485%
|
67
+152%
|
67
0%
|
68
+1%
|
42
-38%
|
1
-97%
|
4
+221%
|
30
+684%
|
32
+6%
|
34
+7%
|
31
-9%
|
4
-88%
|
2
-49%
|
(0)
N/A
|
2
N/A
|
3
+29%
|
3
N/A
|
|
| Change in Cash | |||||||||||||||||||||||||||
| Net Change in Cash |
2
N/A
|
13
+444%
|
(37)
N/A
|
4
N/A
|
13
+270%
|
(0)
N/A
|
(1)
-56%
|
(2)
-396%
|
(8)
-218%
|
23
N/A
|
2
-89%
|
4
+65%
|
6
+49%
|
(21)
N/A
|
(5)
+77%
|
(16)
-221%
|
6
N/A
|
7
+14%
|
12
+67%
|
14
+20%
|
(12)
N/A
|
(14)
-11%
|
(16)
-18%
|
(10)
+38%
|
(7)
+32%
|
(6)
+19%
|
|
| Free Cash Flow | |||||||||||||||||||||||||||
| Free Cash Flow |
(32)
N/A
|
(31)
+2%
|
(39)
-25%
|
(47)
-22%
|
(50)
-7%
|
(57)
-12%
|
(59)
-4%
|
(60)
-2%
|
(63)
-5%
|
(64)
-2%
|
(67)
-5%
|
(68)
-1%
|
(64)
+6%
|
(56)
+12%
|
(47)
+16%
|
(43)
+8%
|
(44)
-1%
|
(46)
-4%
|
(49)
-7%
|
(45)
+8%
|
(38)
+15%
|
(30)
+21%
|
(20)
+34%
|
(12)
+38%
|
(10)
+21%
|
(8)
+13%
|
|